Rossari Biotech Q1 FY27: Record Revenue, Margin Repair Still in Progress

Rossari Biotech opened FY27 with its strongest quarterly revenue to date, but the quarter also underlined a familiar theme for investors: the gap between strong growth and still-evolving profitability. For Q1 FY27, the company reported consolidated revenue from operations of INR 697.2 crore, up 28.2% year on year, and EBITDA of INR 80.6 crore, up 18.7%. PAT rose 4.5% to INR 35.1 crore.

The headline numbers look clean. But the margin line is where the real debate sits. EBITDA margin came in at 11.6%, down from 12.5% in Q1 FY26, while PAT margin fell to 5.0% from 6.2%. Management attributed the margin profile to a combination of product mix, cost volatility and the continued drag from the institutional and B2C verticals.

Growth was broad-based across the core segments

Rossari’s operating mix is still anchored in its B2B specialty chemicals portfolio. In Q1 FY27, Home, Personal Care and Performance Chemicals remained the growth engine, delivering INR 553 crore in revenue. Textile Specialty Chemicals delivered INR 106 crore, while Animal Health and Nutrition contributed INR 38 crore. Management highlighted that HPPC, TSC and AHN each grew roughly 27% to 28% year on year, indicating that the quarter’s growth was not driven by a single pocket.

Exports continued to be a meaningful contributor. On the earnings call, the company indicated export revenue of about INR 160 crore in Q1, translating to roughly 23% to 24% of consolidated sales. Export growth was stated at about 20% to 21% year on year, supported by higher wallet share with partners, new customer additions, and growing acceptance of Rossari’s specialty solutions overseas.

Financial summary

The key margin debate: core B2B versus the institutional and B2C drag

A key disclosure this quarter was the split between consolidated performance and performance excluding the institutional and B2C businesses. The institutional and B2C verticals delivered INR 71 crore of revenue in Q1 FY27, largely flat year on year, but EBITDA remained negative at around INR 4 crore.

In contrast, the consolidated business excluding these verticals delivered INR 626 crore of revenue and EBITDA of INR 85 crore, with EBITDA margin of about 14%. Management positioned this as a better representation of the core B2B earnings power.

This distinction matters because management’s medium-term profitability narrative is largely about removing the drag and improving utilisation across assets created over the last few years. In the Q&A, the CFO stated that exiting the B2C portion could release about 2% to 3% of EBITDA margin uplift, and also reiterated that steady-state EBITDA margin is expected to be around 15% once portfolio actions and mix improvements materialise.

Execution updates: Thailand facility, asset monetisation, and a sharper portfolio

Rossari highlighted two tangible operational updates in the presentation.

First, the company established a greenfield blending facility in Thailand through its subsidiary, Unistar Thai. The plant has installed capacity of 5,000 MTPA with capabilities across powders, granules and liquids. Management described it as a small formulation unit meant to get closer to Southeast Asian customers, offer customised formulations aligned to local needs, and improve supply chain efficiency. On the call, the company said Q1 revenue contribution from the Thailand facility was about INR 2 to 3 crore as it only recently went on stream, with gradual ramp-up expected.

Second, the company continued monetising non-core assets. It completed the sale of its Andheri office during Q1. Management also referred to the sale of the Kanjurmarg office in the previous quarter. On the call, it disclosed the transaction sizes: Kanjurmarg office sold for about INR 24 crore in Q4 FY26, and Andheri office sold for about INR 10.5 crore in Q1 FY27. Management stated that such actions are intended to release capital, improve balance sheet efficiency and redeploy resources toward higher-return areas.

This portfolio sharpening also extends to business lines. Management acknowledged that institutional and consumer verticals are operating in a subdued environment and weighing on profitability. It said it is evaluating rationalisation of select non-core businesses and assets to simplify the portfolio and improve the quality of earnings. In Q&A, management clarified it is looking to exit the B2C consumer business, while continuing the institutional cleaning chemicals business.

Guidance, volatility and what management is willing to commit

Despite Q1’s 28% revenue growth, management did not revise its earlier revenue growth expectation for FY27. The CFO reiterated an annualised view of around 15% growth for FY27, citing difficulty in predicting in a volatile environment.

A large part of that caution came from two operational variables discussed during the call: freight volatility and raw material swings. Management described freight and insurance costs rising sharply with geopolitical developments, impacting order economics. It also cited a one-off impact from phenol price movement, where inventory purchases made in anticipation of further increases were hit when prices moved the other way.

On the margin outlook, management indicated that the Q1 EBITDA margin level of 11.6% should be considered a base and expects improvement as utilisation increases and portfolio actions progress. It also stated that the core business (excluding institutional and B2C) already operates around 14% margin, and the company’s plan is to move to around 15% steady-state margins over about two years.

Segment snapshot (Q1 FY27)

Capital allocation signals: slower capex, focus on utilisation, and optionality in KSA

Management indicated that capex in India is being slowed and will be more calibrated, largely focused on select new molecules and product development rather than large new spends. The near-term execution priority is improving utilisation across the expanded manufacturing base built over the last few years.

The Saudi Arabia initiative remains an optional strategic lever rather than a committed near-term project. Management stated it is still surveying feedstock and land allocations, and nothing has been finalised. However, it did share a directional timeline: once announced, the project could take about 1.5 years to commence production. The company also stated the proposed project would include a mix of EO and non-EO products.

Takeaways

Rossari’s Q1 FY27 result strengthens the growth narrative, with record revenue and broad-based momentum across HPPC, TSC and AHN. But the quarter also makes the operating agenda clear: profitability improvement depends on two moving parts, portfolio rationalisation of the loss-making B2C component and better utilisation of the expanded asset base.

Management has kept FY27 growth expectations at around 15% despite a strong Q1, reflecting its stance that volatility in freight and raw materials limits predictability. The more investable question over the next few quarters is whether the company can execute on the stated plan: keep core B2B margins stable around the mid-teens, remove the institutional and B2C drag, and progress toward a 15% steady-state EBITDA margin over the next couple of years.